Does Mineralocorticoid Receptor Antagonism Prevent Calcineurin Inhibitor-Induced Nephrotoxicity?

Calne, 1978, Cyclosporin A in patients receiving renal allografts from cadaver donors, Lancet, 2, 1323, 10.1016/S0140-6736(78)91970-0

Starzl, 1989, FK 506 for liver, kidney, and pancreas transplantation, Lancet, 2, 1000, 10.1016/S0140-6736(89)91014-3

Naesens, 2009, Calcineurin inhibitor nephrotoxicity, Clin J Am Soc Nephrol, 4, 481, 10.2215/CJN.04800908

Kapturczak, 2004, Pharmacology of calcineurin antagonists, Transplant Proc, 36, 25S, 10.1016/j.transproceed.2004.01.018

Stoumpos, 2015, Cardiovascular morbidity and mortality after kidney transplantation, Transpl Int, 28, 10, 10.1111/tri.12413

Paoletti, 2013, Effects of ACE inhibitors on long-term outcome of renal transplant recipients: a randomized controlled trial, Transplantation, 95, 889, 10.1097/TP.0b013e3182827a43

Ibrahim, 2013, Angiotensin II blockade in kidney transplant recipients, J Am Soc Nephrol, 24, 320, 10.1681/ASN.2012080777

van Riemsdijk, 2000, Addition of isradipine (Lomir) results in a better renal function after kidney transplantation: a double-blind, randomized, placebo-controlled, multi-center study, Transplantation, 70, 122

Kuypers, 2004, Calcium channel blockade and preservation of renal graft function in cyclosporine-treated recipients: a prospective randomized placebo-controlled 2-year study, Transplantation, 78, 1204, 10.1097/01.TP.0000137793.23371.42

Midtvedt, 2001, Sustained improvement of renal graft function for two years in hypertensive renal transplant recipients treated with nifedipine as compared to lisinopril, Transplantation, 72, 1787, 10.1097/00007890-200112150-00004

Camilleri, 2016, Calcineurin inhibitor-sparing strategies in renal transplantation: where are we? A comprehensive review of the current evidence, Exp Clin Transplant, 14, 471, 10.6002/ect.2015.0283

Vincenti, 2016, Belatacept and long-term outcomes in kidney transplantation, N Engl J Med, 374, 333, 10.1056/NEJMoa1506027

Vincenti, 2017, Ten-year outcomes in a randomized phase II study of kidney transplant recipients administered belatacept 4-weekly or 8-weekly, Am J Transplant, 1, 10.1111/ajt.14452

Kumar, 2017, Belatacept as an alternative to calcineurin inhibitors in patients with solid organ transplants, Front Med, 4, 60, 10.3389/fmed.2017.00060

Naesens, 2016, Calcineurin inhibitor nephrotoxicity in the era of antibody-mediated rejection, Transplantation, 100, 1599, 10.1097/TP.0000000000001244

Nankivell, 2004, Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology, Transplantation, 78, 557, 10.1097/01.TP.0000128636.70499.6E

Schwarz, 2010, Biopsy-diagnosed renal disease in patients after transplantation of other organs and tissues, Am J Transplant, 10, 2017, 10.1111/j.1600-6143.2010.03224.x

Ekberg, 2007, Reduced exposure to calcineurin inhibitors in renal transplantation, N Engl J Med, 357, 2562, 10.1056/NEJMoa067411

Nankivell, 2016, Calcineurin inhibitor nephrotoxicity through the lens of longitudinal histology: comparison of cyclosporine and tacrolimus eras, Transplantation, 100, 1723, 10.1097/TP.0000000000001243

Fuller, 2005, Mechanisms of mineralocorticoid action, Hypertension, 46, 1227, 10.1161/01.HYP.0000193502.77417.17

Ochs, 1978, Spironolactone, Am Heart J, 96, 389, 10.1016/0002-8703(78)90052-2

Stier, 2003, Eplerenone: a selective aldosterone blocker, Cardiovasc Drug Rev, 21, 169, 10.1111/j.1527-3466.2003.tb00114.x

Yang, 2016, Mineralocorticoid receptor antagonists-pharmacodynamics and pharmacokinetic differences, Curr Opin Pharmacol, 27, 78, 10.1016/j.coph.2016.02.005

Brown, 2013, Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis, Nat Rev Nephrol, 9, 459, 10.1038/nrneph.2013.110

Moss, 2015, Mineralocorticoid receptors in the pathophysiology of vascular inflammation and atherosclerosis, Front Endocrinol, 6, 153, 10.3389/fendo.2015.00153

Fels, 2010, Menage a trois: aldosterone, sodium and nitric oxide in vascular endothelium, Biochim Biophys Acta, 1802, 1193, 10.1016/j.bbadis.2010.03.006

Pitt, 1999, The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators, N Engl J Med, 341, 709, 10.1056/NEJM199909023411001

Pitt, 2003, Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction, N Engl J Med, 348, 1309, 10.1056/NEJMoa030207

Liu, 2011, Cellular and molecular mechanisms of renal fibrosis, Nat Rev Nephrol, 7, 684, 10.1038/nrneph.2011.149

Currie, 2016, Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis, BMC Nephrol, 17, 127, 10.1186/s12882-016-0337-0

Bolignano, 2014, Aldosterone antagonists for preventing the progression of chronic kidney disease, Cochrane Database Syst Rev, 4, CD007004, 10.1002/14651858.CD007004.pub3

Lee, 1997, Cyclosporine and the renin-angiotensin axis, Kidney Int, 52, 248, 10.1038/ki.1997.328

Weir, 1990, Acute effects of intravenous cyclosporine on blood pressure, renal hemodynamics, and urine prostaglandin production of healthy humans, Transplantation, 49, 41, 10.1097/00007890-199001000-00009

Bantle, 1985, Effects of cyclosporine on the renin-angiotensin-aldosterone system and potassium excretion in renal transplant recipients, Arch Intern Med, 145, 505, 10.1001/archinte.1985.00360030153026

Issa, 2014, The renin-aldosterone axis in kidney transplant recipients and its association with allograft function and structure, Kidney Int, 85, 404, 10.1038/ki.2013.278

Sun, 2015, Inhibition of local aldosterone by eplerenone reduces renal structural damage in a novel model of chronic cyclosporine A nephrotoxicity, J Renin Angiotensin Aldosterone Syst, 16, 301, 10.1177/1470320314561248

Perez-Rojas, 2005, Renocortical mRNA expression of vasoactive factors during spironolactone protective effect in chronic cyclosporine nephrotoxicity, Am J Physiol Renal Physiol, 289, F1020, 10.1152/ajprenal.00166.2005

McAuley, 1987, The influence of enalapril or spironolactone on experimental cyclosporin nephrotoxicity, Biochem Pharmacol, 36, 699, 10.1016/0006-2952(87)90721-0

Thomson, 1987, Angiotensin-converting enzyme inhibition or aldosterone antagonism reduces cyclosporine nephrotoxicity in the rat, Transplant Proc, 19, 1242

Iacona, 1991, Reduced nephrotoxicity and hepatoxicity in cyclosporin A therapy by enalapril and spironolactone in rats, Drugs Exp Clin Res, 17, 501

Nielsen, 2008, Inhibition of mineralocorticoid receptors with eplerenone alleviates short-term cyclosporin A nephrotoxicity in conscious rats, Nephrol Dial Transplant, 23, 2777, 10.1093/ndt/gfn204

Amador, 2016, Deletion of mineralocorticoid receptors in smooth muscle cells blunts renal vascular resistance following acute cyclosporine administration, Kidney Int, 89, 354, 10.1038/ki.2015.312

Feria, 2003, Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity, Kidney Int, 63, 43, 10.1046/j.1523-1755.2003.00707.x

Macunluoglu, 2008, Effects of spironolactone in an experimental model of chronic cyclosporine nephrotoxicity, Transplant Proc, 40, 273, 10.1016/j.transproceed.2007.11.025

Nielsen, 2013, The mineralocorticoid receptor antagonist eplerenone reduces renal interstitial fibrosis after long-term cyclosporine treatment in rat: antagonizing cyclosporine nephrotoxicity, BMC Nephrol, 14, 42, 10.1186/1471-2369-14-42

Silva, 2008, The effect of aldosterone antagonist in experimental nephropathy induced by cyclosporine A, Ren Fail, 30, 439, 10.1080/08860220801947397

Waanders, 2009, Spironolactone ameliorates transplant vasculopathy in renal chronic transplant dysfunction in rats, Am J Physiol Renal Physiol, 296, F1072, 10.1152/ajprenal.90643.2008

Perez-Rojas, 2007, Mineralocorticoid receptor blockade confers renoprotection in preexisting chronic cyclosporine nephrotoxicity, Am J Physiol Renal Physiol, 292, F131, 10.1152/ajprenal.00147.2006

Kunter, 2003, Expression of A20 in the vessel wall of rat-kidney allografts correlates with protection from transplant arteriosclerosis, Transplantation, 75, 3, 10.1097/01.TP.0000043982.08656.81

Vega, 2016, The cellular and signalling alterations conducted by TGF-beta contributing to renal fibrosis, Cytokine, 88, 115, 10.1016/j.cyto.2016.08.019

Meng, 2016, TGF-beta: the master regulator of fibrosis, Nat Rev Nephrol, 12, 325, 10.1038/nrneph.2016.48

Bertocchio, 2016, Safety of Eplerenone for kidney-transplant recipients with impaired renal function and receiving cyclosporine A, PLoS One, 11, e0153635, 10.1371/journal.pone.0153635

Medeiros, 2017, Randomized controlled trial of mineralocorticoid receptor blockade in children with chronic kidney allograft nephropathy, Clin J Am Soc Nephrol, 12, 1291, 10.2215/CJN.05300516

Gonzalez Monte, 2010, Addition of spironolactone to dual blockade of renin angiotensin system dramatically reduces severe proteinuria in renal transplant patients: an uncontrolled pilot study at 6 months, Transplant Proc, 42, 2899, 10.1016/j.transproceed.2010.08.024

Ojeda-Cervantes, 2013, Mineralocorticoid receptor blockade reduced oxidative stress in renal transplant recipients: a double-blind, randomized pilot study, Am J Nephrol, 37, 481, 10.1159/000350539